Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS.

Journal and index pages often block iframe embedding. This reader keeps the evidence details in Orthonotes and leaves the source page one click away.

Abstract

[Indexed for MEDLINE] 9. Bone. 2022 May;158:115735. doi: 10.1016/j.bone.2020.115735. Epub 2020 Nov 7. Pharmacologic management of metastatic bone disease. Schwartz E(1), Reichert Z(2), Van Poznak C(2). Author information: (1)Michigan Medicine: Rogel Cancer Center, United States of America. Electronic address: schwarte@med.umich.edu. (2)Michigan Medicine: Rogel Cancer Center, United States of America. Bone is a common site of metastases, particularly in advanced breast and prostate cancer. Skeletal related events associated with bone metastases include pathologic fracture, need for surgery/radiation to bone and cord compression. These events cause significant morbidity and mortality. Bisphosphonates as well as denosumab act on the bone microenvironment and reduce the rate of skeletal related events by approximately 25%-40%. Hence, these therapies are an important adjunctive therapy in cancer care. Despite the established efficacy and recommendations for their use in many international guidelines, these bone modifying agents are underutilized. This review examines the currently available guidelines on bone modifying agents in metastatic bone disease and summarizes their efficacy, risk and comparative benefits. Copyright © 2020 Elsevier Inc. All rights reserved. DOI: 10.1016/j.bone.2020.115735